Human lysozyme ELISA kit is a method for determining in-vitro quantitative concentrations of IgG autoantibodies to lysozyme (LYZ, muramidase, N-acetylmuramide glycanhydrolase) in human plasma or serum samples. This assay has a minimum analytical sensitivity limit of 0.5 U/ml.
Lysozyme (LYZ) is also commonly referred to as N-acetylmuramide glycanhydrolase or muramidase, it is part of the innate immune system that functions as an antimicrobial enzyme. It is a glycoside hydrolase which is able to catalyse the hydrolysis of N-acetyl-D-glucosamine and N-acetylmuramic acid residues that are present in peptidoglycan. Peptidoglycan forms a major component of gram-positive bacterial cell wall and its hydrolysis results in compromising the bacterial cell wall integrity, this process causes lysis of the bacteria. Lysozyme is abundant in a number of secretions such as human milk, saliva, mucus and tears. It is also found in cytoplasmic granules of polymorphonuclear neutrophils (PMNs) and macrophages. Lysozyme belongs to the family of pANCA group and autoantibodies against it are displayed at higher frequency in inflammatory bowel disease (for example ulcerative colitis) and rheumatoid vasculitis. In certain cancers (for example myelomonocytic leukemia) excessive production of lysozyme can results in in toxic levels of lysozyme being found in the blood. This has been shown to lead to low blood potassium and kidney failure. Serum lysozyme is less specific for diagnosing sarcoidosis when compared to using serum angiotensin converting enzyme, however, it does display a higher sensitivity and therefore is frequently used as a marker and for monitoring sarcoidosis disease activity in proven cases. The following lysozyme ELISA kit is designed to be used for many diagnostic applications.
The minimum detection sensitivity level of human lysozyme (muramidase or N-acetylmuramide glycanhydrolase) IgG autoantibodies using current human lysozyme ELISA kit was 0.5 U/ml. The dynamic range for this assay is 6.3 – 100.0 U/ml.
- Recent advances for the production and recovery methods of lysozyme. Crit Rev Biotechnol. (2016) 36 (6): 1078-1088. Review. Ercan D. and Demirci A.
- Pharmacological aspects and therapeutic applications of lysozymes. EXS. (1996) 75: 433-49. Review. Sava G.
- Antimicrobial proteins: From old proteins, new tricks. Mol Immunol. (2015) 68 (2 Pt B): 383-98. Review. Smith V.J. and Dyrynda E.A.
- Lysozymes in the animal kingdom. J Biosci. (2010) 35 (1): 127-60. Review. Callewaert L. and Michiels C.W.
- Guards of the great wall: bacterial lysozyme inhibitors. Trends Microbiol. (2012) 20 (10): 501-10. Review. Callewaert L., et al.
- Full Name: Lysozyme Ab ELISA Kit
- Reactivity: Human
- Sample Type: Plasma, Serum
- Sensitivity: 0.5 U/ml